Monday, October 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· April 4, 2026

New platform Suomi-kasinot.fi launches to simplify online casino choices for Finnish players

View original at globenewswire.com
New platform Suomi-kasinot.fi launches to simplify online casino choices for Finnish players Helsinki, April 05, 2026 (GLOBE NEWSWIRE) -- As Finland’s gambling market moves toward a major regulatory shift, a new comparison platform, Suomi-kasinot.fi, has been launched to help Finnish players navigate the growing number…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Players are increasingly looking for fast payments, smooth user experiences, and trustworthy operators

    60% confidence

  • All featured casinos operate under recognized EU/EEA licenses, such as those issued in Malta or Estonia, which in many cases allow Finnish players to benefit from tax-free winnings under current legislation

    60% confidence

  • Pay N Play systems have seen strong growth in the Finnish market

    60% confidence

  • The goal is to offer clear, practical, and unbiased information in a market that can often feel fragmented and difficult to navigate

    60% confidence

  • Choosing an online casino is not just about bonuses, but about the overall experience including fund access speed, platform usability, and operator trustworthiness

    60% confidence

  • The regulatory shift is likely to attract new international operators and expand consumer choice, while increasing the importance of transparent and reliable comparison services

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com